scispace - formally typeset
N

Nora D. Volkow

Researcher at National Institute on Drug Abuse

Publications -  1038
Citations -  121498

Nora D. Volkow is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine & Addiction. The author has an hindex of 165, co-authored 958 publications receiving 107463 citations. Previous affiliations of Nora D. Volkow include National Institutes of Health & North Shore University Hospital.

Papers
More filters
Journal ArticleDOI

Striatocortical pathway dysfunction in addiction and obesity: differences and similarities.

TL;DR: It is shown that regions found to be abnormal in addiction and obesity frequently emerge at the overlap of the dorsal and the ventral striatal networks, indicating more widespread abnormalities for obesity and eating disorders than for addictions.
Journal ArticleDOI

Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues.

TL;DR: It is shown that in cocaine abusers (n=20) oral methylphenidate (20 mg), which significantly increased dopamine in striatum, did not induce craving unless subjects were concomitantly exposed to cocaine cues, which suggests that dopamine increases associated with conditioned cues are not primary responses but reflect downstream stimulation of dopamine cells (presumably glutamatergic afferents from prefrontal cortex and/or amygdala).
Journal ArticleDOI

Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder

TL;DR: It is indicated that dopamine enhancement in ventral striatum (the brain region involved with reward and motivation) was associated with therapeutic response to methylphenidate, further corroborating the relevance of the dopamine reward/motivation circuitry in ADHD.
Journal ArticleDOI

Decreased brain dopaminergic transporters in HIV-associated dementia patients

TL;DR: The results provide the first evidence of DA terminal injury in HIV dementia patients, and suggest that decreased DAT may contribute to the pathogenesis of HIV dementia.